Premia Global Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Premia Global Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$636K	Hold	92,375	–	–	1.1%	26
2019 Q2	$852K	Hold	92,375	–	–	1.33%	21
2019 Q1	$1.45M	Hold	92,375	–	–	1.47%	11
2018 Q4	$1.42M	Hold	92,375	–	–	4.09%	6
2018 Q3	$1.99M	Hold	92,375	–	–	4.16%	6
2018 Q2	$2.25M	Buy	92,375 +42,375	+85%	+$864K	2.93%	10
2018 Q1	$854K	Hold	50,000	–	–	0.74%	15
2017 Q4	$947K	Buy	+50,000	New	+$752K	0.92%	18

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return

Premia Global Advisors's TEVA Position: Q3 2019 in Review

Premia Global Advisors held its Teva Pharmaceuticals (TEVA) position steady in Q3 2019 at 92,375 shares worth $636K. The position accounts for 1.1% of the portfolio, ranked #26.

Premia Global Advisors first reported a position in TEVA in Q4 2017 and has held it in 8 quarters since. The position peaked at $2.25M in Q2 2018. 427 funds tracked by Wall St. Rank hold TEVA as of Q3 2019.

Premia Global Advisors held 92,375 shares of Teva Pharmaceuticals worth $636K as of Q3 2019.
Premia Global Advisors left its Teva Pharmaceuticals share count unchanged in Q3 2019.
Teva Pharmaceuticals made up 1.1% of Premia Global Advisors's portfolio in Q3 2019, its #26 holding.
Premia Global Advisors first reported a position in Teva Pharmaceuticals in Q4 2017 and has held it in 8 quarters since.
Premia Global Advisors's Teva Pharmaceuticals position peaked at $2.25M in Q2 2018.
427 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2019.

Based on Premia Global Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.